These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6421424)

  • 1. Human ultralente insulin.
    Holman RR; Steemson J; Darling P; Reeves WG; Turner RC
    Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM.
    Rizza RA; O'Brien PC; Service FJ
    Diabetes Care; 1986; 9(2):120-3. PubMed ID: 3698778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The subcutaneous absorption of human and bovine ultralente insulin formulations.
    Hildebrandt P; Berger A; Vølund A; Kühl C
    Diabet Med; 1985 Sep; 2(5):355-9. PubMed ID: 2951089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
    Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
    Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence.
    Smith CP; Dunger DB; Mitten S; Hewitt J; Spowart K; Grant DB; Savage MO
    Diabet Med; 1988; 5(4):352-5. PubMed ID: 2968885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
    Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
    Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man.
    Owens DR; Vora JP; Heding LG; Luzio S; Ryder RE; Atiea J; Hayes TM
    Diabet Med; 1986; 3(4):326-9. PubMed ID: 2949920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultralente based insulin regimens--clinical applications, advantages and disadvantages.
    Turner RC; Phillips MA; Ward EA
    Acta Med Scand Suppl; 1983; 671():75-86. PubMed ID: 6349269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind crossover trial comparing human insulin (recombinant DNA) with animal insulins in the treatment of previously insulin-treated diabetic patients.
    Clark AJ; Wiles PG; Leiper JM; Knight G; Adeniyl-Jones RO; Watkins PJ; Ward JD; MacCuish AC; Keen H; Jones RH
    Diabetes Care; 1982; 5 Suppl 2():129-34. PubMed ID: 6765523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
    Holman RR; Steemson J; Turner RC
    Diabet Med; 1987; 4(5):457-62. PubMed ID: 2959438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two twice-daily insulin regimens: ultralente/soluble and soluble/isophane.
    Ward GM; Simpson RW; Ward EA; Turner RC
    Diabetologia; 1981 Oct; 21(4):383-6. PubMed ID: 7026334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ultralente insulin in cats with diabetes mellitus.
    Nelson RW; Feldman EC; DeVries SE
    J Am Vet Med Assoc; 1992 Jun; 200(12):1828-9. PubMed ID: 1639685
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of unusual case of brittle diabetes with sulfated beef insulin.
    Davidson MB; Kumar D; Smith W
    Diabetes Care; 1991 Nov; 14(11):1109-10. PubMed ID: 1797500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.